Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Invesco NASDAQ 100 ETF (QQQM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Invesco NASDAQ 100 ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.45 (market cap $5.07B), while Invesco NASDAQ 100 ETF trades at $298.37. The key difference: ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Invesco NASDAQ 100 ETF nearer its low. Which is the better fit depends on your goals.
| ACAD | QQQM | |
|---|---|---|
Market Cap | $5.07B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $29.45 | $307.23 |
52-Week Low | $20.06 | $229.87 |
Enterprise Value | $4.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.47, up 0.26% with strong technical momentum and bullish moving average signals. The company reported robust Q2 2026 earnings of $0.18 per share, beating estimates by 164%, driven by strong Daybue and Nuplazid sales. Revenue reached $1.07 billion in 2025 with impressive net income margins of 33.42%. Recent FDA Fast Track designation for remlifanserin in Alzheimer's disease psychosis adds to positive catalysts.
ACAD presents compelling growth potential with 70% analyst buy ratings and a $33.89 consensus price target implying 15% upside. Strong revenue growth trajectory and expanding profitability support bullish case, though elevated EV/EBITDA of 42.55 and recent RSI overbought signals warrant caution. Key risk remains clinical trial outcomes for pipeline assets.
QQQM trades at $297.98, up 0.4% with a bullish technical outlook supported by moving averages. The ETF tracks the Nasdaq-100 index with lower fees than its QQQ counterpart, making it attractive for long-term investors. Recent news highlights its popularity among growth-focused investors and retirees seeking exposure to technology and innovation stocks.
The ETF's performance remains tied to the 'Magnificent Seven' tech stocks, with historical annual returns around 14%. While technical indicators show bullish momentum, the elevated RSI suggests potential near-term consolidation. Key risks include concentration in tech sector and market volatility affecting growth stocks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Invesco NASDAQ 100 ETF
QQQM is an ETF designed to track the performance of the NASDAQ-100 Index. It provides exposure to the 100 largest non-financial companies listed on the NASDAQ. Positioned as a lower-cost and more long-term-investor-friendly alternative to its peer QQQ, QQQM offers the same fundamental market exposure but typically has a lower share price and is structured to appeal to investors focused on accumulation rather than active trading.
Read more on QQQM →
